Navigation Links
Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
Date:11/1/2007

-- VELCADE third-quarter U.S. net sales increased 32% year-over-year to

$70.4 million --

-- Full-year financial guidance raised for second time in 2007 -- -- Phase III VISTA trial in newly diagnosed multiple myeloma stopped early due to positive interim analysis; sNDA filing now expected in December 2007

-- -- VELCADE listed in national compendia for use in newly diagnosed multiple

myeloma -- -- VELCADE label broadened by FDA providing further differentiation as

leading multiple myeloma therapy --

CAMBRIDGE, Mass., Nov. 1 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced its financial and operational results for the third quarter of 2007. The Company raised its full-year 2007 financial guidance for the second time this year.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

"Millennium delivered outstanding results for the quarter. U.S. net sales of VELCADE grew 32 percent over the same period last year as we fortified our leading position in relapsed multiple myeloma. The strength of our Phase III VISTA data clearly demonstrates that VELCADE has the potential to expand this leadership position into the front-line setting," said Deborah Dunsire, M.D., President and Chief Executive Officer, Millennium. "We are raising our full- year 2007 financial guidance for the second time this year, validating the success of our strategic initiatives to accelerate growth."

"We continue to outperform financial expectations driven by accelera
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014  ECC West Africa, LLC (ECC) signed a ... University College Hospital (UCH) Ibadan Board of Management for ... design, construct, and operate and maintain a new, state-of-the-art ... Under the first of the 4-phase project, ECC will ... applications. UCH Ibadan intends to finance and develop the ...
(Date:7/24/2014)... natural and synthetic processes prefer to settle into ... energyit is within the realm of non-equilibrium conditions ... changes in energy and phases, such as temperature ... allow humans to regulate their body temperature, airplanes ... seismic activity. , But even though these ...
(Date:7/24/2014)... , July 24, 2014  CorMedix Inc. (NYSE ... and commercializing therapeutic products for the prevention and ... receipt of notice on July 18, 2014 from ... has accepted the CorMedix plan to regain compliance ... a result, the NYSE-MKT is continuing the Company,s ...
(Date:7/24/2014)... 1000 balances – 4 steps – ... weighing needs and expertly narrows down the mass of ... or even terminals. , First, select the working ... select readability instead) and define the accuracy – it’s ... narrows down the list to models that fit best ...
Breaking Biology Technology:ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2New approach to form non-equilibrium structures 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3
... Lumidigm, Inc. is proud to announce that its ... technologies and products recognized by Popular Science as ... Venus product is the first high-volume multispectral imaging ... ease of integration, the Venus fingerprint sensor features ...
... LAUSANNE, Switzerland and BANGALORE, India, November ... biopharmaceutical development,specialist that focuses on serious ... Discovery Technologies Ltd (Aurigene), a,Bangalore-based fully ... molecule,and peptide drug discovery and development ...
... (OTC Bulletin Board: SYMD) announced today that it has ... membrane intended to prevent post-operative adhesions in nasal and ... and sinus procedures performed annually in the United States. ... P. Hickey, SyntheMed,s President & CEO stated, "SinusShield represents ...
Cached Biology Technology: Lumidigm Biometric Sensor Included in Popular Science Best of What's New for 2008 : Venus Series Fingerprint Sensor Called a Breakthrough Product by the World's Largest Science and Technology Magazine 2 Lumidigm Biometric Sensor Included in Popular Science Best of What's New for 2008 : Venus Series Fingerprint Sensor Called a Breakthrough Product by the World's Largest Science and Technology Magazine 3Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway 2Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway 3SyntheMed Announces FDA Clearance of SinusShield(TM) 2
(Date:7/25/2014)... bifda (SB) is a complex congenital central nervous ... closing of the neural tubes during the embryonic ... urinary and fecal incontinence and neurocognitive retardation. Such ... quality of life. Researchers at Ankara Physical Medicine ... the functional performance in children with SB, using ...
(Date:7/25/2014)... first time, Spanish researchers have detected an unknown interaction ... cells are introduced into a droplet of salt water ... chloride crystallisation to create biomineralogical biosaline 3D morphologically complex ... material, bacteria are revived. The discovery was made by ... cover of the Astrobiology journal and may ...
(Date:7/24/2014)... July 24, 2014 /PRNewswire-iReach/ -- The Geneva Healthcare Suite, ... devices, has cut emergency room wait times by an ... (UCSD) Medical Center, according to a recent study published ... Departments are using the suite to access data from ... defibrillators. "Using Geneva,s technology platform we have ...
Breaking Biology News(10 mins):Bacteria manipulate salt to build shelters to hibernate 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3
... The leaking of environmentally damaging pollutants into our waters ... mathematical algorithm, according to researchers. Presenting their research ... Problems , the researchers, from Universit de Technologie ... avoid environmental catastrophes by identifying the exact location where ...
... renowned biologist and population geneticist, has been named founding ... This newly created position will further strengthen GW,s role ... region and nationally. As director, Dr. Crandall ... Institute and direct the development and implementation of research ...
... as an important predictor of survival among human patients with ... Veterinary Medicine at Tufts University have developed two surveys that ... of life for dogs and cats with heart disease. ... (Cats, Assessment Tool for Cardiac Health), the surveys ask owners ...
Cached Biology News:Maths formula leads researchers to source of pollution 2GW announces creation of Computational Biology Institute to conduct integrated research 2GW announces creation of Computational Biology Institute to conduct integrated research 3GW announces creation of Computational Biology Institute to conduct integrated research 4New tools for evaluating quality of life for cats, dogs with heart disease 2
...
Mouse monoclonal antibody raised against a full length recombinant ATF3. NCBI Entrez Gene ID = ATF3...
... dsRNA Marker consists of ten double-stranded RNAs, ... 400, 500 and 1,000 base pairs. The ... for determinating sizes of double-stranded RNAs. A ... dsRNA Marker is adjusted to approximately 25 ...
... antibody raised against a partial ... Immunogen: HD (NP_002102, 81 ... recombinant protein with GST tag. ... NM_002111 ...
Biology Products: